Anticoagulants and immunosuppressive therapy for thrombosis in Behçet’s syndrome: a systematic review and meta-analysis
Journal of Thrombosis and Haemostasis · 2025-11 · 23 (11) · 3578-3589
DOI: 10.1016/j.jtha.2025.07.025 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025-11. Verfasst von Arisa Chuklin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Anticoagulants, Behcet Syndrome, Immunosuppressive Agents, Thrombosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Behçet's syndrome is a systemic vasculitis commonly associated with thrombotic manifestations. The primary treatment of vascular Behçet's syndrome involves immunosuppression; however, the role of anticoagulation remains unestablished. OBJECTIVES: We conducted a systematic review and meta-analysis to evaluate the effectiveness of immunosuppressives alone, anticoagulants alone, and combined immunosuppressives and anticoagulants in preventing thrombosis relapse in Behçet's syndrome. METHODS: A systematic search was conducted using PubMed, EMBASE, and Cochrane Library from inception until April 1, 2025. Original studies enrolling ≥10 Behçet's syndrome patients with venous or arterial thrombosis were included if they reported intervention-specific recurrence or relapse rates of thrombosis. The primary outcome was the pooled relapse rate for each intervention group (immunosuppressives alone, anticoagulants alone, and combined immunosuppressives and anticoagulants), calculated using a random-effects model with 95% CIs. Subgroup analyses were performed to compare the pooled rates among the groups. RESULTS: A total of 20 studies (19 retrospective and 1 prospective) were included. Ten studies (315 patients) provided disaggregated data for the meta-analysis. The pooled relapse rate in the group receiving immunosuppressives and anticoagulants combined (17.7%; 95% CI, 9.7%-30.1%; I2 = 56%) was significantly lower than that of those who received immunosuppressives alone (43.7%; 95% CI, 25.8%-63.4%; I2 = 63%; P = .017) or anticoagulants alone (54.9%; 95% CI, 0.322%-0.758%; I2 = 48%; P = .004). CONCLUSION: Combined immunosuppressives and anticoagulants were associated with lower risks of thrombosis relapse compared with either treatment alone in Behçet's syndrome-associated thrombosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Center of Excellence in Translational Hematology, Division of Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Tha…
Zitieren
APA
Chuklin, A., Chiasakul, T., & Uaprasert, N. (2025). Anticoagulants and immunosuppressive therapy for thrombosis in Behçet’s syndrome: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 23(11), 3578-3589. https://doi.org/10.1016/j.jtha.2025.07.025
Vancouver
Chuklin A, Chiasakul T, Uaprasert N. Anticoagulants and immunosuppressive therapy for thrombosis in Behçet’s syndrome: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis. 2025;23(11):3578-3589. doi:10.1016/j.jtha.2025.07.025
BibTeX
@article{Chuklin2025,
author = {Chuklin, Arisa and Chiasakul, Thita and Uaprasert, Noppacharn},
title = {Anticoagulants and immunosuppressive therapy for thrombosis in Behçet’s syndrome: a systematic review and meta-analysis},
journal = {Journal of Thrombosis and Haemostasis},
year = {2025},
volume = {23},
number = {11},
pages = {3578--3589},
doi = {10.1016/j.jtha.2025.07.025}
}
EUVIMED